AstraZeneca India to Sets Up Genomic Solutions Centre in Amaravati

AstraZeneca India announced an Integrated Genomic Solutions Centre in Amaravati, Andhra Pradesh, on 28 July 2026. The centre is part of India’s first Integrated Precision Oncology programme and focuses on genetic research for cancer diagnosis and therapy.

Integrated Precision Oncology

Precision oncology is a cancer treatment approach that uses genetic and molecular information to match diagnosis and therapy with a patient’s disease profile. Integrated genomic centres use next-generation genetic testing, bioinformatics, and clinical data for cancer screening and treatment planning.

Focus Areas in Cancer Care

The centre will primarily target lung cancer and breast cancer. These two cancers are among the most commonly diagnosed malignancies in India and are major areas of screening, early detection, and treatment research.

Technology and Hospital Screening

The initiative includes AI-powered X-rays and next-generation genetic testing for use in government hospitals. AstraZeneca India is working with Strand Life Sciences and Qure.ai to deploy smart screening tools for earlier diagnosis and improved patient management.

Important Facts for Exams

• Amaravati is the planned capital region of Andhra Pradesh.
• Precision medicine uses biological data, including genetic information, for disease management.
• Next-generation genetic testing is used to analyse DNA and identify disease-related variants.
• Qure.ai is known for artificial intelligence-based medical imaging solutions.

Healthcare Ecosystem

The project is linked with Andhra Pradesh’s healthcare and life sciences ecosystem. Genomic centres, AI-based screening, and hospital partnerships are used in cancer programmes in several countries.